ACCELLENA NEWS

A new study on monoclonal antibody

Accellena is starting a first-in-human trial to study the safety and tolerability of a monoclonal antibody against COVID-19. It is planned to study the drug in increasing dose cohorts in more than 100 subjects.

2022-03-15 12:34 Projects